Login
Vaxart, Inc. logo

Vaxart, Inc.

vaxart.com

What Do They Do?

Develops oral tablet vaccine candidates for infectious diseases and HPV-related disease, working with government agencies and pharmaceutical partners.

How Do They Make Money?

Most revenue comes from government contracts: BARDA pays for COVID-19 trial work through reimbursement of eligible costs as they are incurred and fixed-price milestones when completed. Dynavax paid an upfront fee for a vaccine license, with further development, milestone and possible sales-royalty payments.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Non Cash Royalty Revenue
Licensed
0.8%
FY2022: 100%
Government Contract
95%
License
Licensed
3.7%
Collaboration Revenue
Recurring
0.9%

Who Are Their Customers?

Vaxart contracts with Advanced Technology International for BARDA-funded vaccine-trial work; Dynavax holds an exclusive worldwide license to the COVID-19 candidate, and Daiichi Sankyo markets Inavir in Japan.

Do Revenues Turn Into Profits?

Yes. It kept 7 cents of every revenue dollar as net income in FY2025 and turned 3 cents into free cash flow.

Operating income, FY2025
8% of revenue
▲ Turned profitable vs FY2024 (−$66.3M, −231%)
Net income, FY2025
7% of revenue
▲ Turned profitable vs FY2024 (−$66.9M, −233%)
Free cash flow, FY2025
3% of revenue
▲ Turned profitable vs FY2024 (−$45.3M, −158%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −85%
vs $72.4M in Q3 FY2025
Net income
▼ −117% (Loss)
vs −$8.1M in Q3 FY2025
Government Contract share of revenue vs 100.0% in Q3 FY2025
  • Jun 26, 2026 BARDA cut funding available under the COVID-19 trial contract The modification set available funding at approximately $345 million, approximately $116 million below the prior modification.

Growing. Revenue grew 266.0x in 4 years, from $892K in FY2021 to $237.3M in FY2025, about 304% a year.

Revenue over time
Non Cash Royalty Revenue Government Contract License Collaboration Revenue Customer Service Contracts Grant
$250M$125M$0

Who Do They Compete With?

Competes with Moderna, Anhui Zhifei Longcom Biopharmaceutical, Chongqing Zhifei Biological Products, National Vaccine and Serum Institute of China, Cocrystal Pharma, Pfizer-BioNTech, Novavax, AstraZeneca, CSL, Emergent BioSolutions, F. Hoffmann-La Roche, GSK, Instituto Butantan, Merck &, Pfizer, Sanofi, Sinovac Biotech, Centivax, Inovio Pharmaceuticals, and Genexine

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support